Navigation Links
CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume,in Coronary Arteries

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- CSL Limited today announced results from a study published in the Journal of the American Medical Association that suggest infusions of a novel new drug, CSL-111, to acutely raise HDL ("good" cholesterol) levels, may reduce the amount of plaque in the coronary arteries of patients with a recent episode of acute coronary syndrome (ACS).

ACS is the term used to describe unstable angina and myocardial infarction (heart attack). It is estimated to be responsible for up to 600,000 admissions to the hospital per year in the US. Despite improvements in management over many years, ten to fifteen percent of patients still experience a serious cardiovascular problem in the 12 months following an episode of ACS.

CSL-111 is a patented biologic product, consisting of apolipoprotein A-I purified from human plasma that is reconstituted to form a particle that chemically and biologically resembles human HDL. A 40 mg/kg dose of CSL-111 results in an approximately 50 percent elevation in blood HDL levels, which remain above normal for one week. It was discovered and is manufactured at CSL Behring in Switzerland.

The Effect of Reconstituted HDL on Atherosclerosis - Safety and Efficacy (ERASE) trial was a phase 2, randomized, blinded, placebo-controlled study conducted at 17 sites throughout Canada and coordinated by the Montreal Heart Institute. The trial examined whether four infusions of CSL-111, given at weekly intervals to patients with a recent episode of ACS, could reduce the volume of plaque in the coronary arteries. Assessment of the arteries was performed using intravascular ultrasound (IVUS) and quantitative coronary angiography (QCA) before and two-three weeks after the treatment. IVUS is a technique in which a tiny ultrasound probe is inserted into the coronary arteries to determine the change in plaque during treatment. Coronary angiography is an X-ray
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

Post Your Comments:
(Date:11/25/2009)...v. 25 ERT (Nasdaq: ERES...the Company,s President and CEO, and Keith Schneck...are scheduled to present at the 21st Annual Piper ...ecember 1, 2009 in New York City, New York. ,, ...visiting the Company,s corporate website at http:...
(Date:11/25/2009)...Nov. 25 Remedium Techno...like foam that stops severe bleeding, won first pr...a category of the Global Security Challenge 2009, ...rom more than 100 entries from around the world, R...Security Summit conference held at the London Scho...
(Date:11/25/2009)...25 Reportlinker.com announces that...catalogue: ,, Mammography Equipment - A Globa...ker.com/p0164330/Mammography-Equipment---A-Global-... breast cancer in industrialized as well as develo...wth in the mammography market. Globally, escalatin...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 6430 1Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 6430 2Biologists discover bacterial defense mechanism against aggressive oxygen 10837 1Biologists discover bacterial defense mechanism against aggressive oxygen 10837 2Carvedilol shown to have unique characteristics among beta blockers 10832 1Carvedilol shown to have unique characteristics among beta blockers 10832 2
...Conference Call Scheduled for 10:00 a.m. today, Th...uxilium,Pharmaceuticals, Inc. (Nasdaq: AUXL ) tod...ce from the U.S. Food and Drug Administration ("FD...AFLEX (clostridial collagenase,for injection), for...upuytren,s contracture. The Company will hold a co...
...Company on Target to File Supplemental New Drug Ap... Quarter, FRAZER, Pa., Aug. 16 Cephalon, Inc...from a 12-week, Phase 3 clinical,trial of FENTORA(...h,breakthrough pain associated with a broad range ...chieved statistical significance on the primary,en...
Other Medicine Technology:Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 2Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 3Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 4Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 5Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 6Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5
(Date:11/27/2009)...INE, France, Nov. 27 Team Garmin-S... team dedicated to ethical sporting and developing...ed today that it will become Team Garmin-Transitio...ew sponsor of the team. Transitions Optical is the... offering the most advanced photochromic technolog...
(Date:11/27/2009)...-emission vehicles may reduce future disease burde...HealthDay News) -- Encouraging city dwellers to wa...uch greater public health benefits than increased ...ve found. , The study compared the projected he...nsport scenarios for London, England, and Delhi, I...
(Date:11/27/2009)...yant Health™ announced today that Spectrum H...aumaCad Enterprise orthopedic templating solution ... (PRWEB) November 27, 2009 -- ... Health (Grand Rapids, Michigan) has licensed its ...n and its TraumaCad Extend workflow solution, to a...
(Date:11/27/2009)...ree new interactive anatomy education apps from Mo...d health sciences learning opportunities for iPhon..., NC (Vocus) November 27, 2009 -- Modality, Inc. ...vision of Wolters Kluwer Health, today announced t...s on the App Store. Clemente’s Anatomy, Rohe...
(Date:11/26/2009)...number of Americans living with diabetes will near... 44.1 million in 2034. Over the same period, spend...13 billion to $336 billion, even with no increase ... the University of Chicago report in the December ...with diabetes covered by Medicare will rise from 8...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...dited by the Society of Chest Pain Centers (SCPC) ...ack core measures established by Centers for Medic...-accredited hospitals, according to a national stu... the Emory University School of Medicine, are repo...
... -- Many coaches inspire better performance by pre...re using pressure to improve the performance of th...ming problem, the researchers have found that addi...t Daniel Lopez-Ferrer, a post-doctoral researcher ...
... Cross country ride raised more than a hal...ams. , Baltimore, MD (Voc...ice program of the Foundation of the American Acad...olis as they conclude their transcontinental bike ...
...e soon on legislation that would cut $268 million,...HINGTON, July 9 Seniors across Minnesota,are spea...antage program in,legislation being considered in ...reas where Medicare private,fee-for-service plans ...
...y 9 Zeus Scientific, Inc. today,announced its int...ethicillin-resistant Staphylococcus aureus (MRSA)....nology utilizing the enrichment and nucleic acid,a... to identify carriers of this,pathogen within two ...
...July 9, 2008)Dr. Lee Kern, program coordinator and...ty,s College of Education in Bethlehem, Pa., will ...hing the National Research and Development Center ...t of Education to create the centera collaboration...
Other Medicine News:Health News:Chest pain center accreditation linked with better outcomes in heart attack patients 2Health News:Pressured proteins: A little pressure in proteomics squeezes 4-hour step into a minute 2Health News:Pressured proteins: A little pressure in proteomics squeezes 4-hour step into a minute 3Health News:National Non-Profit, EyeCare America, and the Maryland Society of Eye Physicians & Surgeons Host Finish Line Celebration for “EyeRide for Sight” Cyclists 2Health News:National Non-Profit, EyeCare America, and the Maryland Society of Eye Physicians & Surgeons Host Finish Line Celebration for “EyeRide for Sight” Cyclists 3Health News:National Non-Profit, EyeCare America, and the Maryland Society of Eye Physicians & Surgeons Host Finish Line Celebration for “EyeRide for Sight” Cyclists 4Health News:Minnesota Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Lehigh to lead $9.6M national research center for serious behavior disorders 2Health News:Lehigh to lead $9.6M national research center for serious behavior disorders 3
Atraumatic Grasping Forceps (Fallopian), dual-incision
Optima III 45 Noninsulated Strong Forceps, with ratchet
Snap-In Snap-Out®-II Angulated Dissecting Forceps
Snap-In Snap-Out®-II Micro Dolphin Dissecting Forceps Insert
Medicine Products: